Researchers create new path to target hard-to-drug prostate cancer protein

In the United States, prostate cancer is a leading cause of cancer-related disease and death in men. About half of prostate cancer cases in patients of European ancestry have a gene rearrangement where the genes TMPRSS2 and ERG are fused together. This causes the ERG protein to be turned on, increasing the growth and migration of tumor cells.